News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Nasdaq futures slipped as investors grew cautious about AI-related capital spending.
  • Chip stocks and ETFs declined on concerns about rising competition from China.
  • Markets await major tech earnings and a Federal Reserve decision that will shape rate expectations.
  • Ondas faces dilution headlines after an acquisition and announced share issuance.
  • A tactical 45-day long is proposed for Ondas on raised 2026 revenue guidance and a larger order backlog.
  • Century Aluminum is promoted as a long-term buy amid domestic capacity expansion and tariff incentives.
  • UN officials and public figures urged upholding refugee protections on the 75th anniversary of the 1951 convention.

Latest Articles

Navigator Gas Releases 2025 Sustainability Report

Navigator Gas Releases 2025 Sustainability Report

Navigator Holdings Ltd., a NYSE-listed leader in handysize liquefied gas carriers, released its 2025 Sustainability Report showcasing significant progress in corporate governance, diversity, emission reductions, and investment in environmentally sustainable technologies including ammonia and dual-fuel ethylene vessels. The company reported a 2.97% …

NANO Nuclear’s KRONOS MMR™ and the University of Illinois Urbana-Champaign Advance to Next Regulatory Milestone as U.S. NRC Formally Accepts Construction Permit Application for Review

NANO Nuclear’s KRONOS MMR™ and the University of Illinois Urbana-Champaign Advance to Next Regulatory Milestone as U.S. NRC Formally Accepts Construction Permit Application for Review

NANO Nuclear Energy Inc. announced that the U.S. Nuclear Regulatory Commission has formally accepted the Construction Permit Application for their KRONOS MMR™ micro modular reactor at the University of Illinois Urbana-Champaign. This acceptance initiates the formal licensing review process, marking a major milestone as KRONOS MMR™ becomes the first…

Applied Materials Announces Broadcom as EPIC Innovation Partner

Applied Materials Announces Broadcom as EPIC Innovation Partner

Applied Materials announced that Broadcom will join its EPIC innovation platform to collaborate on R&D for advanced packaging technologies essential for next-generation AI chips. This partnership leverages Applied's global innovation centers, including the new EPIC Center in Silicon Valley, aiming to expedite the commercialization of high-performan…

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Protara Therapeutics, a clinical-stage biotech company, announced participation in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit. The company will discuss its lead candidate TARA-002 in Phase 2 trials for non-muscle invasive bladder cancer and lymphatic malformations, as well as its development of IV Choline Chloride…

Smithfield Foods Awards 12 Impact Grants Nationwide

Smithfield Foods Awards 12 Impact Grants Nationwide

Smithfield Foods has awarded over $280,000 in Impact Grants to 12 nonprofit organizations addressing community needs such as hunger relief, education, and local infrastructure. This funding builds on their prior $24 million investment in 2025 and supports initiatives including food security, literacy, emergency services, and youth programs in areas…

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

Annovis Bio, a clinical-stage biotech company focusing on therapies for Alzheimer's and Parkinson's diseases, announced the pricing of an underwritten public offering of common stock and warrants aiming to raise approximately $15 million. The proceeds will primarily support continued clinical development of buntanetap and general corporate purposes…

Freshworks Announces Winners of the 2026 Global Customer Awards

Freshworks Announces Winners of the 2026 Global Customer Awards

Freshworks Inc. announced the winners of its inaugural 2026 Global Customer Awards, recognizing customers from various industries who have successfully leveraged Freshworks' AI-enabled service platforms to drive significant operational efficiencies, improve customer satisfaction, and advance digital transformation. The awards highlight achievements…

Daniel Kelly Joins Talen as General Counsel and Corporate Secretary

Daniel Kelly Joins Talen as General Counsel and Corporate Secretary

Talen Energy Corporation announced the appointment of Daniel Kelly as General Counsel and Corporate Secretary. Kelly brings 25 years of legal and governance experience, previously holding a senior role at Vistra Corp. He replaces John Wander, who has retired after three years in the position. Kelly will oversee legal, regulatory, and corporate gove…

Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

Madrigal Pharmaceuticals announced that new data from its MASH program will be presented at the EASL Congress 2026. The data includes secondary analyses from Phase 3 trials demonstrating Rezdiffra's positive impact on lipid profiles and portal hypertension risk markers in patients with metabolic dysfunction-associated steatohepatitis (MASH). The pr…

Bernstein: Strong HBM Sales to Drive Samsung and SK Hynix Growth in Q2 2026

Bernstein: Strong HBM Sales to Drive Samsung and SK Hynix Growth in Q2 2026

Korean export data for April indicate continued momentum in High Bandwidth Memory (HBM) shipments for Samsung Electronics and SK Hynix heading into the second quarter of 2026, Bernstein said. Multichip memory exports to Taiwan and Malaysia reached $3.7 billion in April, a monthly decline tied to seasonality but a substantial 62% increase from Janua…

EuroDry Ltd. Reports Results for the Quarter Ended March 31, 2026 and Announces the order for two Modern 82,000 DWT Kamsarmax Bulk Carriers

EuroDry Ltd. Reports Results for the Quarter Ended March 31, 2026 and Announces the order for two Modern 82,000 DWT Kamsarmax Bulk Carriers

EuroDry Ltd., a US-listed drybulk shipping company, reported a positive turnaround in Q1 2026 with net income attributable to controlling shareholders of $0.26 million, a significant improvement from a loss in the same period last year. The company saw a 38.9% increase in net revenues driven by a doubling of the average time charter equivalent rate…

Buy the Quality: Verra Mobility Looks Attractive After the Pullback

Buy the Quality: Verra Mobility Looks Attractive After the Pullback

Verra Mobility's business remains high-quality: recurring government contracts, durable commercial fleet relationships, and $105M in free cash flow support a mid-term swing trade. The stock has pulled back near its 52-week low and shows oversold technicals, while valuation on EV/EBITDA (~8.7x) is reasonable versus growth profile. Enter $13.25, stop…

Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval

Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval

Dyne Therapeutics has commenced the Phase 3 FORZETTO clinical trial testing z-rostudirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping. The 72-week, placebo-controlled trial aims to confirm the drug's efficacy and safety with a primary endpoint focused on muscle function. The trial protocol aligns with FDA guidelines to…